

Research Grade Coltuximab

Summary

Catalog No.	DHD10801
Alternative Names	SAR3419, CAS: 1269764-99-9
Clone ID	Coltuximab
Host species	Chimeric
Species reactivity	Human
Form	Liquid
Storage buffer	0.01M PBS, pH 7.4.
Concentration	1 mg/ml
Purity	>95% as determined by SDS-PAGE.
Clonality	Monoclonal
Isotype	IgG1-kappa
Applications	Research Grade Biosimilar
Target	CD19, Differentiation antigen CD19, T-cell surface antigen Leu-12, B-lymphocyte antigen CD19, B-lymphocyte surface antigen B4
Purification	Protein A/G purified from cell culture supernatant.
Endotoxin level	Please contact with the lab for this information.
Expression system	Mammalian Cells
Accession	P15391

Stability and Storage

Use a manual defrost freezer and avoid repeated freeze-thaw cycles.

Store at 4°C short term (1-2 weeks). Store at -20°C 12 months. Store at -80°C long term.


Note

For research use only. Not suitable for clinical or therapeutic use.

Description

Coltuximab ravtansine (SAR3419) is an antibody-drug conjugate (ADC) targeting CD19 created by conjugating a derivative of the potent microtubule-acting cytotoxic agent, maytansine, to a version of the anti-CD19 antibody, anti-B4, that was humanized as an IgG1 by variable domain resurfacing. Four different linker-maytansinoid constructs were synthesized (average 3.5 maytansinoids/antibody for each) to evaluate the impact of linker-payload design on the activity of the maytansinoid-ADCs targeting CD19. Anti-CD19 humanized monoclonal antibody conjugated to DM4.

Data Image




SDS-PAGE

SDS PAGE for Coltuximab Ravtansine



Recombinant Proteins & Antibodies



The purity of this product is >95% as determined by SEC-HPLC.

SEC-HPLC